• Johnson & Johnson flagged newly published MEMBRANE trial results in JAMA Neurology on June 19, 2026.
• Findings were already presented via publication, not scheduled for a future conference readout.
• Adding middle meningeal artery embolization using TRUFILL n-BCA to standard care lowered chronic subdural hematoma recurrence or worsening.
• The approach also reduced the need for repeat surgical intervention versus standard care alone.
• Results support broader adoption of the procedure in chronic subdural hematoma treatment pathways.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on June 19, 2026, and is solely responsible for the information contained therein.